Alfasigma worldwide
Belgium
China
Czech Republic
France
Germany
India
Italy
Mexico
Netherlands
Poland
Portugal
Romania
Russia
Slovak Republic
Spain
Switzerland
Tunisia
Usa
Our Company
Alfasigma at glance
Our purpose
Our Beliefs
Our Legacy
Financials
Ethics and Transparency
HCP/HCO relationship
Scientific transparency
Patient associations funding
Global Code of Conduct
Pharmacovigilance
Speak Up System
Therapeutic Areas
All therapeutic areas
Gastroenterology
Vascular
Research & Innovation
Corporate Responsibility
CDMO
Careers
News & Media
Newsroom
Media Center
Contacts
Search for:
Our Company
Alfasigma at glance
Our purpose
Our Beliefs
Our Legacy
Financials
Ethics and Transparency
HCP/HCO relationship
Scientific transparency
Patient associations funding
Global Code of Conduct
Pharmacovigilance
Speak Up System
Therapeutic Areas
All therapeutic areas
Gastroenterology
Vascular
Research & Innovation
Corporate Responsibility
CDMO
Careers
News & Media
Newsroom
Media Center
Contacts
Search for:
February 1, 2024
Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million
×
You’re entering Alfasigma global website
I agree